SG164279A1 - Tricyclic thrombin receptor antagonists - Google Patents
Tricyclic thrombin receptor antagonistsInfo
- Publication number
- SG164279A1 SG164279A1 SG200607217-7A SG2006072177A SG164279A1 SG 164279 A1 SG164279 A1 SG 164279A1 SG 2006072177 A SG2006072177 A SG 2006072177A SG 164279 A1 SG164279 A1 SG 164279A1
- Authority
- SG
- Singapore
- Prior art keywords
- substituted
- bond
- receptor antagonists
- optionally substituted
- thrombin receptor
- Prior art date
Links
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37307202P | 2002-04-16 | 2002-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG164279A1 true SG164279A1 (en) | 2010-09-29 |
Family
ID=29250954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200607217-7A SG164279A1 (en) | 2002-04-16 | 2003-04-14 | Tricyclic thrombin receptor antagonists |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7304078B2 (https=) |
| EP (5) | EP1495018B3 (https=) |
| JP (2) | JP4558331B2 (https=) |
| KR (1) | KR101026929B1 (https=) |
| CN (1) | CN1659162B (https=) |
| AR (1) | AR039570A1 (https=) |
| AT (3) | ATE494284T1 (https=) |
| AU (1) | AU2003221932B2 (https=) |
| BR (1) | BRPI0309309B8 (https=) |
| CA (1) | CA2482858C (https=) |
| CY (3) | CY1107184T1 (https=) |
| DE (3) | DE60335679D1 (https=) |
| DK (2) | DK2065384T3 (https=) |
| EC (1) | ECSP045368A (https=) |
| ES (3) | ES2338171T3 (https=) |
| FR (1) | FR15C0047I2 (https=) |
| IL (1) | IL164585A (https=) |
| LT (1) | LTC1495018I2 (https=) |
| LU (1) | LU92759I2 (https=) |
| MX (1) | MXPA04010308A (https=) |
| MY (1) | MY144040A (https=) |
| NL (1) | NL300746I2 (https=) |
| NO (2) | NO330500B1 (https=) |
| NZ (2) | NZ575139A (https=) |
| PE (1) | PE20040412A1 (https=) |
| PL (1) | PL214718B1 (https=) |
| PT (2) | PT1495018E (https=) |
| RU (2) | RU2329264C9 (https=) |
| SG (1) | SG164279A1 (https=) |
| SI (2) | SI1495018T1 (https=) |
| TW (1) | TWI343919B (https=) |
| WO (1) | WO2003089428A1 (https=) |
| ZA (1) | ZA200408342B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| CN1984905B (zh) * | 2004-05-28 | 2011-06-22 | 先灵公司 | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 |
| US8563511B2 (en) * | 2004-10-06 | 2013-10-22 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| WO2006076452A2 (en) * | 2005-01-14 | 2006-07-20 | Schering Corporation | An exo-selective synthesis of himbacine analogs |
| CA2875768C (en) | 2005-01-14 | 2018-03-06 | George G. Wu | Process for the preparation of phosphonate compounds useful in the preparation of himbacine analogs |
| DE602006020414D1 (en) * | 2005-01-14 | 2011-04-14 | Schering Corp | Synthese von himbacinanaloga |
| JP2008526254A (ja) * | 2005-01-14 | 2008-07-24 | シェーリング コーポレイション | ヒンバシン類似物のキラルプロパルギルアルコールおよびエステル中間体の調製 |
| US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
| US7776889B2 (en) * | 2005-03-31 | 2010-08-17 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| WO2007075808A2 (en) * | 2005-12-20 | 2007-07-05 | Schering Corporation | Methods for preventing and/or treating a cell proliferative disorder |
| JP2009521472A (ja) * | 2005-12-22 | 2009-06-04 | シェーリング コーポレイション | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト |
| TW200812619A (en) * | 2006-04-06 | 2008-03-16 | Schering Corp | TRA combination therapies |
| US8003803B2 (en) | 2006-04-13 | 2011-08-23 | Schering Corporation | Fused ring thrombin receptor antagonists |
| EP2032560B1 (en) * | 2006-06-29 | 2013-05-01 | Merck Sharp & Dohme Corp. | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| TWI367112B (en) * | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| DE102006036023A1 (de) | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| CA2666903A1 (en) * | 2006-10-04 | 2008-05-22 | Schering Corporation | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| EP2069326B1 (en) | 2006-10-04 | 2015-03-18 | Merck Sharp & Dohme Corp. | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| EP2120879A2 (en) * | 2006-12-22 | 2009-11-25 | Schering Corporation | Disintegration promoters in solid dose wet granulation formulations |
| BRPI0809095A2 (pt) * | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
| RU2494100C2 (ru) | 2008-02-05 | 2013-09-27 | Санофи-Авентис | Соли триазолия в качестве ингибиторов par1, их получение и применение в качестве лекарственного средства |
| RS52264B (sr) | 2008-02-05 | 2012-10-31 | Sanofi | Triazolopiridazini kao inhibitori par1, njihovo dobijanje i upotreba kao lekova |
| WO2009124103A2 (en) * | 2008-04-02 | 2009-10-08 | Schering Corporation | Combination therapies comprising par1 antagonists with par4 antagonists |
| EP2805939B1 (en) | 2008-05-19 | 2018-06-27 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as factor IXA inhibitors. |
| EP2438060B1 (en) * | 2009-06-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | Active metabolite of a thrombin receptor antagonist |
| JP2012529431A (ja) | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| ES2532902T3 (es) | 2010-04-16 | 2015-04-01 | Sanofi | Piridil-vinil-pirroles tricíclicos como inhibidores de PAR1 |
| WO2011128420A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren |
| KR101303348B1 (ko) | 2010-06-25 | 2013-09-03 | 한국화학연구원 | 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| WO2015013083A1 (en) * | 2013-07-22 | 2015-01-29 | Merck Sharp & Dohme Corp. | Co-crystal of the par-1 receptor antagonist vorapaxar and aspirin |
| EP3035928B1 (en) * | 2013-08-22 | 2023-10-18 | Merck Sharp & Dohme LLC | 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives |
| EP3035929B1 (en) * | 2013-08-22 | 2024-07-03 | Merck Sharp & Dohme LLC | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| FR3014693B1 (fr) | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
| WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105985303B (zh) * | 2015-02-13 | 2020-08-14 | 上海彩迩文生化科技有限公司 | 抗凝血剂的制备方法、中间体及其制备方法 |
| CN106478608A (zh) * | 2015-09-01 | 2017-03-08 | 博瑞生物医药（苏州）股份有限公司 | 沃拉帕沙的硫酸盐的结晶多晶型物 |
| CN106749201A (zh) * | 2015-11-25 | 2017-05-31 | 博瑞生物医药（苏州）股份有限公司 | 一种沃拉帕沙及其中间体的制备方法 |
| TR201601548A2 (tr) * | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
| WO2017134200A1 (en) * | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
| TW201738221A (zh) * | 2016-04-22 | 2017-11-01 | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 |
| CN106236779A (zh) * | 2016-08-22 | 2016-12-21 | 孔五 | 一种脐带血富血小板血浆prp的制备方法 |
| FR3090317B1 (fr) | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
| CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
| US20210113536A1 (en) * | 2019-10-21 | 2021-04-22 | United States Government as Represented by the Department of Veteran Affairs | Methods and compositions for detecting and treating venous thromboembolism |
| FR3109089B1 (fr) | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
| CN116133660B (zh) | 2020-07-22 | 2025-05-02 | 詹森药业有限公司 | 可用作因子XIa抑制剂的化合物 |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US12286429B2 (en) | 2021-07-22 | 2025-04-29 | Janssen Pharmaceutica Nv | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| FR3134314A1 (fr) | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO2001096330A2 (en) * | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| TW197435B (https=) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| GB9102862D0 (en) * | 1991-02-11 | 1991-03-27 | Erba Carlo Spa | N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| CZ298578B6 (cs) * | 1997-11-25 | 2007-11-14 | Schering Corporation | Heterocyklickou skupinou substituovaná tricyklická sloucenina a farmaceutický prostredek ji obsahující |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| KR100960170B1 (ko) | 2001-10-18 | 2010-05-26 | 쉐링 코포레이션 | 트롬빈 수용체 길항제로서의 힘바신 동족체 |
-
2003
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko not_active Expired - Fee Related
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en not_active Ceased
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
-
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
-
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
-
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
-
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
-
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
-
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I2/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO2001096330A2 (en) * | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG164279A1 (en) | Tricyclic thrombin receptor antagonists | |
| MX2009003761A (es) | Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. | |
| MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
| WO2006105217A3 (en) | Spirocyclic thrombin receptor antagonists | |
| WO2007126771A3 (en) | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists | |
| TW200626584A (en) | Thrombin receptor antagonists | |
| GB9914486D0 (en) | Medicaments | |
| NO20062239L (no) | Nye tetrahydrospiro[piperidin-2,7'-pyrrolo[3,2-b]pyridinderivater og nye indolderivater nyttige i behandlingen av 5-HT6 reseptorrelaterte forstyrrelser | |
| WO2004012759A3 (de) | Erythropoetin zur stimulation endothelialer voläuferzellen | |
| PE20041076A1 (es) | Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
| WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| EA200801909A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
| WO1999026932A8 (en) | By amidino group substituted heterocyclic derivatives and their use as anticoagulants | |
| WO2007044804A3 (en) | Piperidine derivatives and methods of use | |
| EA200901572A1 (ru) | 3-(имидазолил)пиразоло[3,4-b]пиридины | |
| MY140887A (en) | Thrombin receptor antagonists | |
| MX2009003758A (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina. | |
| WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
| ATE342264T1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| DK0733051T3 (da) | Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister | |
| WO2007075809A3 (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. |